ASCO 2023 | VBIR vaccine shows promise in prostate cancer: Phase I trial results and immunotherapy potential

Daniel Petrylak, MD, Yale School of Medicine, New Haven, CT, provides an overview of a Phase I (NCT02616185) trial of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC). The regimen consisted of an intramuscular administration of an adenovirus vector and plasmid DNA expressing prostate-specific membrane antigen (PSMA), prostate-specific antigen (PSA), and prostate stem cell antigen (PSCA). Patients received the vaccine with or without immune checkpoint inhibitors. Overall, the treatment was well-tolerated, with common adverse events including fatigue, influenza-like illness, diarrhea, and immune-related thyroid dysfunction. The vaccine induced antigen-specific immune responses, and modest antitumor activity was observed in both mCRPC and BCR patients, with some achieving significant declines in PSA levels. However, notable side effects were observed in some BCR patients. These findings suggest the potential of PrCa VBIR as an immunotherapy approach in prostate cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.